Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway
Search for other papers by Ivar Følling in
Google Scholar
PubMed
Search for other papers by Anna B Wennerstrøm in
Google Scholar
PubMed
Search for other papers by Tor J Eide in
Google Scholar
PubMed
Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway
Search for other papers by Hilde Loge Nilsen in
Google Scholar
PubMed
Cancer Research and Treatment 2019 18 1533033818823029 . ( https://doi.org/10.1177/1533033818823029 ) 30 Johannessen LE Panagopoulos I Haugvik SP Gladhaug IP Heim S Micci F . Upregulation of INS-IGF2 read-through expression and
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Search for other papers by Hélène Lasolle in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Amandine Ferriere in
Google Scholar
PubMed
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France
Search for other papers by Sandrine Eimer in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
Introduction Acromegaly is predominantly caused by a growth hormone (GH)-secreting pituitary adenoma resulting in excessive insulin-like growth factor-I (IGF-I) secretion that is responsible for numerous co-morbidities, reduced quality of life
Search for other papers by R C S van Adrichem in
Google Scholar
PubMed
Search for other papers by L J Hofland in
Google Scholar
PubMed
Search for other papers by R A Feelders in
Google Scholar
PubMed
Search for other papers by M C De Martino in
Google Scholar
PubMed
Search for other papers by P M van Koetsveld in
Google Scholar
PubMed
Search for other papers by C H J van Eijck in
Google Scholar
PubMed
Search for other papers by R R de Krijger in
Google Scholar
PubMed
Search for other papers by D M Sprij-Mooij in
Google Scholar
PubMed
Search for other papers by J A M J L Janssen in
Google Scholar
PubMed
Search for other papers by W W de Herder in
Google Scholar
PubMed
considered as important biochemical and pathological markers, respectively, for GEP NET clinical behaviour. The insulin-like growth factor (IGF) system has been suggested as an important regulator of GEP NET proliferation and differentiation (2) . Up to
Search for other papers by Mette Faurholdt Gude in
Google Scholar
PubMed
Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark
Search for other papers by Rikke Hjortebjerg in
Google Scholar
PubMed
Search for other papers by Mette Bjerre in
Google Scholar
PubMed
Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Morten Haaning Charles in
Google Scholar
PubMed
Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Daniel R Witte in
Google Scholar
PubMed
Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Annelli Sandbæk in
Google Scholar
PubMed
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
://doi.org/10.1016/S2213-8587(1930349-3 ) 24 Bidlingmaier M Friedrich N Emeny RT Spranger J Wolthers OD Roswall J Körner A Obermayer-Pietsch B Hübener C Dahlgren J Reference intervals for insulin-like growth factor-1 (igf-i) from birth to
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Marie Reeberg Sass in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
Search for other papers by Nicolai Jacob Wewer Albrechtsen in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Endocrinology and Nephrology, Nordsjællands University Hospital, Hillerød, Denmark
Search for other papers by Jens Pedersen in
Google Scholar
PubMed
Search for other papers by Kristine Juul Hare in
Google Scholar
PubMed
Center for Neonatal Screening, Department of Congenital Disorders, Statens Serum Institute, Copenhagen, Denmark
Search for other papers by Nis Borbye-Lorenzen in
Google Scholar
PubMed
Search for other papers by Katalin Kiss in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Filip Krag Knop in
Google Scholar
PubMed
Search for other papers by Steen Seier Poulsen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Niklas Rye Jørgensen in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens Juul Holst in
Google Scholar
PubMed
Search for other papers by Cathrine Ørskov in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Bolette Hartmann in
Google Scholar
PubMed
stimulate PTH secretion ( 32 ), it is possible that the growth hormone (GH)/IGF-1 axis also is involved in the differential suppression of PTH following oral and i.v. glucose. GH secretion from the pituitary gland is known to be suppressed following oral
Search for other papers by Rossella Cannarella in
Google Scholar
PubMed
Search for other papers by Teresa Mattina in
Google Scholar
PubMed
Search for other papers by Rosita A Condorelli in
Google Scholar
PubMed
Search for other papers by Laura M Mongioì in
Google Scholar
PubMed
Search for other papers by Giuseppe Pandini in
Google Scholar
PubMed
Search for other papers by Sandro La Vignera in
Google Scholar
PubMed
Search for other papers by Aldo E Calogero in
Google Scholar
PubMed
IGF1R? American Journal of Medical Genetics 2002 113 173 – 177 . ( doi:10.1002/ajmg.10717 ) 10.1002/ajmg.10717 52 Faivre L Gosset P Cormier-Daire V Odent S Amiel J Giurgea I Nassogne MC Pasquier L Munnich A
Centre for Paediatrics and Child Health, Faculty of Medicine, Centre for Genetic Medicine, 5th Floor Research, Genetic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK
Search for other papers by P G Murray in
Google Scholar
PubMed
Search for other papers by D Hanson in
Google Scholar
PubMed
Search for other papers by T Coulson in
Google Scholar
PubMed
Search for other papers by A Stevens in
Google Scholar
PubMed
Search for other papers by A Whatmore in
Google Scholar
PubMed
Search for other papers by R L Poole in
Google Scholar
PubMed
Search for other papers by D J Mackay in
Google Scholar
PubMed
Centre for Paediatrics and Child Health, Faculty of Medicine, Centre for Genetic Medicine, 5th Floor Research, Genetic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK
Search for other papers by G C M Black in
Google Scholar
PubMed
Centre for Paediatrics and Child Health, Faculty of Medicine, Centre for Genetic Medicine, 5th Floor Research, Genetic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK
Search for other papers by P E Clayton in
Google Scholar
PubMed
(7) . Suggested targets for the CUL7 containing E3 ubiquitin ligase enzyme include cyclin D1 (8) and IRS1 (9) . Altered IGF-I signalling with increased activation of the downstream signalling molecule AKT was identified in Cul7 −/− mouse
Department of Endocrinology, Department of Molecular Medicine and Surgery, Metabolism and Diabetology, Karolinska University Hospital, 171 76 Stockholm, Sweden
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Erik Wahlström in
Google Scholar
PubMed
Search for other papers by Petra Tollet-Egnell in
Google Scholar
PubMed
Search for other papers by Gunnar Norstedt in
Google Scholar
PubMed
2011 96 1587 – 1609 . ( doi:10.1210/jc.2011-0179 ). 6 Veldhuis JD Roelfsema F Keenan DM Pincus S . Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Nathalie Ly in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
HJ Orskov H Ledet T . Effect of growth hormone on steroidogenesis, insulin-like growth factor-I (IGF-I) and IGF-binding protein-1 production and DNA synthesis in cultured human luteinized granulosa cells . Journal of Endocrinology 1994 140 313
Search for other papers by T L C Wolters in
Google Scholar
PubMed
Division of Vascular Medicine, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by C D C C van der Heijden in
Google Scholar
PubMed
Search for other papers by N van Leeuwen in
Google Scholar
PubMed
Search for other papers by B T P Hijmans-Kersten in
Google Scholar
PubMed
Search for other papers by M G Netea in
Google Scholar
PubMed
Search for other papers by J W A Smit in
Google Scholar
PubMed
Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK
Search for other papers by D H J Thijssen in
Google Scholar
PubMed
Search for other papers by A R M M Hermus in
Google Scholar
PubMed
Search for other papers by N P Riksen in
Google Scholar
PubMed
Search for other papers by R T Netea-Maier in
Google Scholar
PubMed
effects ( 2 ). Apart from disease-specific complications, patients with active acromegaly suffer from an increased morbidity and mortality due to cardiovascular disease (CVD) ( 3 , 4 ). With disease control (i.e. normalized circulating GH and IGF1